Shots:

• The EC has approved Verquvo (2.5/5/10 mg) in the EU for the treatment of symptomatic CHF in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. The therapy is being jointly developed by both companies
• Merck has the commercial rights to Verquvo in the US and Bayer has the exclusive commercial rights in the ROW. Additionally- both companies share equally cost for the development of vericiguat
• Vericiguat is the sGC stimulator- received the US FDA’s approval in Jan’21 & MHLW approval in Jun’21. The therapy has also been submitted for marketing authorization in China along with multiple other countries globally

Ref: Businesswire| Image: Merck